Panobinostat lactate
Based on 86 publication(s) in Google Scholar
Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.67%
- CAS. Nr.: 960055-56-5
- Formel: C24H29N3O5
- Molecular Weight:439.50
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
FDA-Approved Drug Library
HY-L022
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Off-patent Drug Library
HY-L141
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Panobinostat lactate
More- Signal Transduct Target Ther. 2025 Oct 14;10(1):341. [Abstract]
- Cancer Res. 2025 Jun 2;85(11):2100-2116. [Abstract]
- Cancer Res. 2023 Mar 2;83(5):686-699. [Abstract]
- Cancer Res. 2016 Dec 1;76(23):7001-7011. [Abstract]
- Nat Commun. 2024 Jul 2;15(1):5570. [Abstract]
- Nat Commun. 2023 Apr 13;14(1):2095. [Abstract]
- Hemasphere. 2024 Sep 26;8(9):e70006. [Abstract]
- Sci Transl Med. 2022 Aug 10;14(657):eabg3277. [Abstract]
- Leukemia. 2023 Jun;37(6):1336-1348. [Abstract]
- J Exp Clin Cancer Res. 2022 Nov 11;41(1):321. [Abstract]
- J Nanobiotechnology. 2024 Dec 16;22(1):753. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Clin Cancer Res. 2024 Nov 15;30(22):5166-5179. [Abstract]
- Cancer Lett. 2025 Sep 2:218001. [Abstract]
- Cancer Lett. 2021 Oct 10:518:180-195. [Abstract]
- Cell Death Dis. 2024 Sep 11;15(9):665. [Abstract]
- Cell Death Dis. 2022 Aug 17;13(8):717. [Abstract]
- Acta Pharmacol Sin. 2021 May;42(5):814-823. [Abstract]
- NPJ Breast Cancer. 2023 Aug 11;9(1):66. [Abstract]
- J Transl Med. 2026 Feb 4;24(1):385. [Abstract]
- Biomed Pharmacother. 2022 Nov:155:113843. [Abstract]
- Cell Rep. 2024 May 24;43(6):114272. [Abstract]
- J Med Chem. 2025 Oct 17. [Abstract]
- J Med Chem. 2024 Sep 12;67(17):15098-15117. [Abstract]
- Anal Chem. 2025 Sep 2;97(34):18490-18498. [Abstract]
- Mol Ther Nucleic Acids. 2025 Dec 15.
- JCI Insight. 2025 Oct 9:e195385. [Abstract]
- Cancer Cell Int. 2021 Jun 5;21(1):291. [Abstract]
- Front Immunol. 2021 Aug 31;12:701671. [Abstract]
- Cells. 2026 Apr 10;15(8):673. [Abstract]
- Cells. 2020 Jul 10;9(7):1661. [Abstract]
- Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]
- J Clin Endocrinol Metab. 2021 Jan 1;106(1):e232-e246. [Abstract]
- Drug Des Devel Ther. 2018 Apr 30:12:1009-1017. [Abstract]
- J Drug Deliv Sci Technol. 2025 Nov:113:107341. [Abstract]
- Int J Mol Sci. 2024 Nov 9;25(22):12035. [Abstract]
- Int J Oncol. 2020 Jun;56(6):1429-1441. [Abstract]
- PLoS Pathog. 2018 Sep 13;14(9):e1007267. [Abstract]
- Pharmaceuticals (Basel). 2021 Nov 30;14(12):1244. [Abstract]
- Int Immunopharmacol. 2025 Oct 10:167:115637. [Abstract]
- Eur J Pharmacol. 2020 May 15;875:173050. [Abstract]
- Rheumatology (Oxford). 2025 Aug 13:keaf437. [Abstract]
- Neurooncol Adv. 2021 Jul 17;3(1):vdab099. [Abstract]
- Sci Rep. 2026 Feb 8;16(1):7792. [Abstract]
- Biomedicines. 2021 Dec 10;9(12):1873. [Abstract]
- J Virol. 2021 Sep 9;95(19):e0022721. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Cancer Res Commun. 2025 Jun 1;5(6):1034-1048. [Abstract]
- Cancer Res Commun. 2023 Aug 17;3(8):1580-1593. [Abstract]
- Hum Cell. 2023 Jan;36(1):366-376. [Abstract]
- Cell Biol Int. 2021 May;45(5):1111-1121. [Abstract]
- Mol Immunol. 2023 Dec:164:98-111. [Abstract]
- Insects. 2023 Mar 23;14(4):309. [Abstract]
- J Appl Toxicol. 2023 Aug;43(8):1214-1224. [Abstract]
- Neuroscience. 2021 Jun 15:465:38-45. [Abstract]
- Int J Biochem Cell Biol. 2020 May;122:105734. [Abstract]
- BMC Pharmacol Toxicol. 2023 Sep 22;24(1):45. [Abstract]
- PLoS One. 2022 Feb 14;17(2):e0263822. [Abstract]
- Gene. 2022 Jan 15:808:145977. [Abstract]
- J Recept Signal Transduct Res. 2022 Feb;42(1):100-108. [Abstract]
- Insect Mol Biol. 2020 Feb;29(1):104-111. [Abstract]
- Arch Insect Biochem Physiol. 2021 Jul;107(3):e21823. [Abstract]
- Proteome Sci. 2024 May 15;22(1):6. [Abstract]
- bioRxiv. 2026 May 26:2026.05.22.726988. [Abstract]
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- Charles University. 2026.
- University of Gottingen. 2026.
- Uppsala University. 2025.
- Patent. US20250152731A1.
- Patent. US20250161243A1.
- bioRxiv. 2025 January 15.
- Patent. US20240344035A1
- Patent. US20240344035A1.
- The Ohio State University. 2024 May.
- SSRN. 2023 Sep 29.
- Research Square Preprint. 2023 Aug 14.
- University of Gothenburg. 2023 Jun 27.
- bioRxiv. 2023 Jun 5.
- bioRxiv. 2023 Apr 14.
- Uppsala University. 2022 Feb.
- Research Square Preprint. 2021 Dec.
- Universitat Politècnica de València. 2020 Sep.
- Albert-ludwigs-university Of Freiburg. 2019 Dec.
- bioRxiv. 2019 Nov.
- Patent. US20180263995A1.
- China Biotechnology. 2016, 36(6): 9-17.
Customer Validation & Images
-
WB
-
WB
-
WB
-
WB
Biologische Aktivität
|
HDAC |
HIV-1 |
Panobinostat lactate induces apoptosis of both MOLT-4 and Reh cells in a time- and dose-dependent manner. Panobinosta lactate results in histone (H3K9 and H4K8) hyperacetylation and regulation of cell-cycle control genes in Reh cells[1].
Panobinostat lactate exhibites potent antiproliferative activity in human NSCLC cell lines with the IC50 ranging from 5 to 100 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Panobinostat lactate (5, 10 and 20 mg/kg i.p.) demonstrates a clear benefit of decreased tumor burden, significantly improves TTE and reduces bone density loss in a disseminated multiple myeloma mouse model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 960055-56-5
-
Appearance Solid
-
Molecular Weight 439.50
-
Formel C24H29N3O5
-
Color White to off-white
-
SMILES
O=C(NO)/C=C/C1=CC=C(CNCCC2=C(C)NC3=C2C=CC=C3)C=C1.OC(C)C(O)=O
-
Synonyms
LBH589 lactate; NVP-LBH589 lactate
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (86)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer. [Abstract]2025 Oct 14;10(1):341. PMID: 41083431 -
Cancer Res
Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma. [Abstract]2025 Jun 2;85(11):2100-2116. PMID: 40053472 -
Cancer Res
HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype. [Abstract]2023 Mar 2;83(5):686-699. PMID: 36598365 -
Cancer Res
2016 Dec 1;76(23):7001-7011. PMID: 27671680 -
Nat Commun
2024 Jul 2;15(1):5570. PMID: 38956053 -
Nat Commun
Histone 4 lysine 5/12 acetylation enables developmental plasticity of Pristionchus mouth form. [Abstract]2023 Apr 13;14(1):2095. PMID: 37055396 -
Hemasphere
Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia. [Abstract]2024 Sep 26;8(9):e70006. PMID: 39329074 -
Sci Transl Med
Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. [Abstract]2022 Aug 10;14(657):eabg3277. PMID: 35947676 -
Leukemia
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]2023 Jun;37(6):1336-1348. PMID: 36977823 -
J Exp Clin Cancer Res
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. [Abstract]2022 Nov 11;41(1):321. PMID: 36357906
Panobinostat lactate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Nov 11;41(1):321. [Abstract]
The expression of BRD4 and MYC proteins are each downregulated by JQ1 (0.5 µM; 24 h) or panobinostat (PAN; 10 nM; 24 h) alone, and more profoundly by the combination of these two inhibitors in in MB HD-MB03 and D-283 cells.
-
J Nanobiotechnology
HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability. [Abstract]2024 Dec 16;22(1):753. PMID: 39676171 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Clin Cancer Res
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. [Abstract]2024 Nov 15;30(22):5166-5179. PMID: 39269307 -
Cancer Lett
Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis. [Abstract]2025 Sep 2:218001. PMID: 40907734 -
Cancer Lett
Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer. [Abstract]2021 Oct 10:518:180-195. PMID: 34216690 -
Cell Death Dis
Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway. [Abstract]2024 Sep 11;15(9):665. PMID: 39261475 -
Cell Death Dis
Global crotonylome reveals hypoxia-mediated lamin A crotonylation regulated by HDAC6 in liver cancer. [Abstract]2022 Aug 17;13(8):717. PMID: 35977926 -
Acta Pharmacol Sin
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. [Abstract]2021 May;42(5):814-823. PMID: 32855532 -
NPJ Breast Cancer
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. [Abstract]2023 Aug 11;9(1):66. PMID: 37567892 -
J Transl Med
Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards. [Abstract]2026 Feb 4;24(1):385. PMID: 41639724 -
Biomed Pharmacother
Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. [Abstract]2022 Nov:155:113843. PMID: 36271587 -
Cell Rep
Decrypting lysine deacetylase inhibitor action and protein modifications by dose-resolved proteomics. [Abstract]2024 May 24;43(6):114272. PMID: 38795348 -
J Med Chem
Systems Biology-Based Drug Repositioning Identifies Extracellular Matrix Module as a Therapeutic Target in Lung Squamous Cell Carcinoma. [Abstract]2025 Oct 17. PMID: 41105954 -
J Med Chem
Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]2024 Sep 12;67(17):15098-15117. PMID: 39145486 -
Anal Chem
Exploring the Potential of Chemically Matched Fragments as Internal Standards for Quantitative SERS with Panobinostat. [Abstract]2025 Sep 2;97(34):18490-18498. PMID: 40839542 -
-
JCI Insight
Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high grade IDH mutant gliomas. [Abstract]2025 Oct 9:e195385. PMID: 41066183 -
Cancer Cell Int
Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]2021 Jun 5;21(1):291. PMID: 34090418 -
Front Immunol
Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat. [Abstract]2021 Aug 31;12:701671. PMID: 34531855 -
Cells
HDAC Inhibition Induces Transient Phenotypic Inertia in Dormant OCCC Spheroids by Derepression of Cell Cycle Genes. [Abstract]2026 Apr 10;15(8):673. PMID: 42041541 -
Cells
Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. [Abstract]2020 Jul 10;9(7):1661. PMID: 32664214 -
Commun Biol
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. [Abstract]2021 Oct 29;4(1):1235. PMID: 34716410
Panobinostat lactate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]
TNBC model cells (MDA-MB-231 and BT-549) were treated with indicated HDACi (Vorinostat: 10 µM; Panobinostat: 1 µM; Romidepsin: 1 µM; Givinostat: 1 µM) for 24 h and expression of LIFR, p-STAT3(Y705), and STAT3 were determined using Western blotting.
-
J Clin Endocrinol Metab
2021 Jan 1;106(1):e232-e246. PMID: 33000123 -
Drug Des Devel Ther
Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). [Abstract]2018 Apr 30:12:1009-1017. PMID: 29750014 -
J Drug Deliv Sci Technol
2025 Nov:113:107341. PMID: 40859982 -
Int J Mol Sci
Panobinostat Attenuates Experimental Autoimmune Encephalomyelitis in Mice via Suppressing Oxidative Stress-Related Neuroinflammation and Mitochondrial Dysfunction. [Abstract]2024 Nov 9;25(22):12035. PMID: 39596104 -
Int J Oncol
Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition. [Abstract]2020 Jun;56(6):1429-1441. PMID: 32236593 -
PLoS Pathog
Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. [Abstract]2018 Sep 13;14(9):e1007267. PMID: 30212584
Panobinostat lactate purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2018 Sep 13;14(9):e1007267. [Abstract]
Immunoblot analysis for vIL-6, ORF45, or actin is performed on lysates from BCBL-1 cells treated with NaB+TPA, Romidepsin or Panobinostat.
-
Pharmaceuticals (Basel)
Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer. [Abstract]2021 Nov 30;14(12):1244. PMID: 34959644 -
Int Immunopharmacol
Panobinostat suppresses cGAS-STING pathway activation and ameliorates DSS-induced colitis in mice. [Abstract]2025 Oct 10:167:115637. PMID: 41075748 -
Eur J Pharmacol
Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity. [Abstract]2020 May 15;875:173050. PMID: 32142770 -
Rheumatology (Oxford)
Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]2025 Aug 13:keaf437. PMID: 40802538 -
Neurooncol Adv
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. [Abstract]2021 Jul 17;3(1):vdab099. PMID: 34485908 -
Sci Rep
A novel human acute myeloid leukemia cell line SDEY-AML1 with KMT2A: MLLT3, IKZF1: EVX1 fusions exhibits high tumorigenicity in NSG mice. [Abstract]2026 Feb 8;16(1):7792. PMID: 41656387 -
Biomedicines
An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. [Abstract]2021 Dec 10;9(12):1873. PMID: 34944689 -
J Virol
Development of a Novel In Vitro Primary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription. [Abstract]2021 Sep 9;95(19):e0022721. PMID: 34287050 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Cancer Res Commun
Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. [Abstract]2025 Jun 1;5(6):1034-1048. PMID: 40478628 -
Cancer Res Commun
Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress. [Abstract]2023 Aug 17;3(8):1580-1593. PMID: 37599787 -
Hum Cell
2023 Jan;36(1):366-376. PMID: 36329365 -
Cell Biol Int
Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity. [Abstract]2021 May;45(5):1111-1121. PMID: 33501756 -
Mol Immunol
2023 Dec:164:98-111. PMID: 37992541 -
Insects
BmCBP Catalyzes the Acetylation of BmApoLp-II Protein and Regulates Its Stability in Silkworm, Bombyx mori. [Abstract]2023 Mar 23;14(4):309. PMID: 37103124 -
J Appl Toxicol
Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. [Abstract]2023 Aug;43(8):1214-1224. PMID: 36861143 -
Neuroscience
Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis. [Abstract]2021 Jun 15:465:38-45. PMID: 33862148 -
Int J Biochem Cell Biol
Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance. [Abstract]2020 May;122:105734. PMID: 32119989 -
BMC Pharmacol Toxicol
Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway. [Abstract]2023 Sep 22;24(1):45. PMID: 37740231 -
PLoS One
Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma. [Abstract]2022 Feb 14;17(2):e0263822. PMID: 35157705 -
Gene
Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer. [Abstract]2022 Jan 15:808:145977. PMID: 34592353 -
J Recept Signal Transduct Res
Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs. [Abstract]2022 Feb;42(1):100-108. PMID: 33969806 -
Insect Mol Biol
The effect of acetylation on the protein stability of BmApoLp-III in the silkworm, Bombyx mori. [Abstract]2020 Feb;29(1):104-111. PMID: 31390480 -
Arch Insect Biochem Physiol
The acetylation modification regulates the stability of Bm30K-15 protein and its mechanism in silkworm, Bombyx mori. [Abstract]2021 Jul;107(3):e21823. PMID: 34075635 -
Proteome Sci
iTRAQ-based proteomic study on monocyte cell model discovered an association of LAMP2 downregulation with HIV-1 latency. [Abstract]2024 May 15;22(1):6. PMID: 38750478 -
bioRxiv
Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]2026 May 26:2026.05.22.726988. PMID: 42244620 -
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Panobinostat lactate purchased from MedChemExpress. Usage Cited in: China Biotechnology. 2016, 36(6): 9-17.
The HDAC expression of PC3 cell with different concentration of Panobinostat. (a) HDACs mRNA expression is analyzed by real time PCR (b) HDACs protein expression is analyzed by Western blot.
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (227.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.38 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (11.38 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (806 KB)
- English - EN (806 KB)
- Français - FR (806 KB)
- Deutsch - DE (806 KB)
- Norwegian - NO (806 KB)
- Español - ES (806 KB)
- Swedish - SV (806 KB)
- Italian - IT (806 KB)
- Korean - KR (806 KB)
- Portuguese - PT (806 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111(10):5093-100. [Content Brief]
[2]. Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8(8):2221-31. [Content Brief]
[3]. Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95(5):794-803. [Content Brief]
[4]. Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147. [Content Brief]
[5]. Barton K, et al. Broad activation of latent HIV-1 in vivo. Nat Commun. 2016;7:12731. Published 2016 Sep 8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2753 mL | 11.3766 mL | 22.7531 mL | 56.8828 mL |
| 5 mM | 0.4551 mL | 2.2753 mL | 4.5506 mL | 11.3766 mL | |
| 10 mM | 0.2275 mL | 1.1377 mL | 2.2753 mL | 5.6883 mL | |
| 15 mM | 0.1517 mL | 0.7584 mL | 1.5169 mL | 3.7922 mL | |
| 20 mM | 0.1138 mL | 0.5688 mL | 1.1377 mL | 2.8441 mL | |
| 25 mM | 0.0910 mL | 0.4551 mL | 0.9101 mL | 2.2753 mL | |
| 30 mM | 0.0758 mL | 0.3792 mL | 0.7584 mL | 1.8961 mL | |
| 40 mM | 0.0569 mL | 0.2844 mL | 0.5688 mL | 1.4221 mL | |
| 50 mM | 0.0455 mL | 0.2275 mL | 0.4551 mL | 1.1377 mL | |
| 60 mM | 0.0379 mL | 0.1896 mL | 0.3792 mL | 0.9480 mL | |
| 80 mM | 0.0284 mL | 0.1422 mL | 0.2844 mL | 0.7110 mL | |
| 100 mM | 0.0228 mL | 0.1138 mL | 0.2275 mL | 0.5688 mL |
Powered by Bioz